Distinguishing between solid-pseudopapillary neoplasms (SPNs) and pancreatic neuroendocrine tumors (PanNETs) may pose a diagnostic dilemma. Both can demonstrate solid growth patterns, and both can be immunoreactive with neuroendocrine markers such as synaptophysin and CD56. One well-established feature of SPNs is the presence of hyaline globules, which in contrast has only rarely been reported in PanNETs. Clinicopathologic features of 361 cases originally classified as PanNETs were examined. Of these, 24 tumors (6.6%) had hyaline globules, raising the possibility of SPN. Immunohistochemistry for b-catenin was performed on these 24 neoplasms, and showed nuclear labeling in 6 cases. These 6 cases, which also demonstrated cytoplasmic CD10 staining, were reclassified as SPNs. The remaining 18 cases maintained their original diagnosis as PanNETs, and the hyaline globules in these cases were periodic acid-Schiff (PAS) positive, diastase resistant, and immunoreactive with a-1-antitrypsin. All 24 cases were histologically re-evaluated, and the pattern of invasion, presence of clear cells, and nuclear grooves were found to be helpful in distinguishing SPNs from PanNETs. We conclude that the presence of hyaline globules should raise SPNs in the differential diagnosis of a solid cellular neoplasm of the pancreas. However, this should not be used as the sole criterion in the diagnosis of SPNs, as hyaline globules may also be seen in 5% of PanNETs. Immunohistochemical and histologic features supporting the diagnosis of SPNs over PanNETs include CD10 and nuclear bcatenin labeling, an insidious pattern of invasion, clear cells, and nuclear grooves. (Am J Surg Pathol 2011;35:981-988) D ifferentiating between pancreatic neuroendocrine tumors (PanNETs) and solid-pseudopapillary tumors (SPNs) may be diagnostically challenging. Although SPN is classically described as a solid and cystic neoplasm consisting of poorly cohesive cells forming degenerative papillae, foamy histiocytes, and longitudinal nuclear grooves, SPNs may also exhibit a solid pattern of growth with uniform round-to-oval cells, mimicking PanNETs. 17, 18, 28, 35 Conversely, pseudopapillary areas may also be seen in PanNETs, 35 and PanNETs may occasionally be cystic. 14 In addition, neuroendocrine markers such as synaptophysin may be expressed focally in SPNs. 31, 34, 46 Immunohistochemistry for b-catenin has proven useful, as there is nuclear labeling in SPNs and membranous labeling in PanNETs. 1, 33, 49 Among the additional immunohistochemical markers which can assist in establishing the correct diagnosis are CD10, estrogen and progesterone receptors, and a-1-antitrypsin. 21, 34, 40 As the biological behavior, genetics, and therapeutic implications of PanNETs and SPNs can differ, it is imperative to make the correct Hyaline globules are a feature that has classically been associated with SPNs. 2, 25, 27 These globules are typically periodic acid-Schiff (PAS) positive intracytoplasmic inclusions which are immunoreactive for a-1antitrypsin. Eosinophilic globules are not specific to SPNs, but have also been reported in other pancreatic lesions, including intraductal oncocytic papillary neoplasms, 48 hepatoid carcinoma, 36 and clear cell ductal adenocarcinoma. 42 In contrast, eosinophilic globules have only rarely been described in PanNETs. 10 We reviewed a large series of neoplasms originally diagnosed as PanNETs for hyaline globules. We show that eosinophilic globules may be seen not only in SPNs but also in PanNETs, and describe morphologic features that favor SPN in cases in which the distinction between SPNs and PanNETs may be difficult.
available pathology reports and slides were reviewed. This review yielded 24 neoplasms originally diagnosed as PanNETs, which contained hyaline globules. Single immunolabeling was performed using the antibodies listed in Table 1 . Immunohistochemical studies for synaptophysin and b-catenin were performed on all cases with hyaline globules, and immunolabeling for CD10 was performed as a confirmatory test in cases with nuclear b-catenin labeling. PAS, PAS with diastase, and immunohistochemistry with a-1-antitrypsin and trypsin were performed on all cases with hyaline globules to further characterize these globules. As these globules were focal, they were not present on levels immunolabeled with a-1antitrypsin in 3 cases, on those immunolabeled with trypsin in 2 cases, and on those stained with PAS and PAS with diastase in 2 cases. Immunohistochemistry for Ki-67 and CK19 was also performed.
The Ki-67 labeling index was measured manually using custom software written in ImageJ (Wayne Rasband, NIH, Bethesda, MD) to assist in performing the nuclear counts. Five images were acquired per case at a total magnification of 400 Â using a Q-Color3 digital camera (Olympus, Center Valley, PA) on an Olympus B-50 microscope (Center Valley, PA). Fields were selected that represented the highest density of Ki-67-positive cells. Using an ImageJ macro, each image was presented to the user, who then labeled each Ki-67-positive nucleus with a color marker by clicking on it with the mouse. Each Ki-67-negative nucleus was labeled using a marker of a different color. Non-neoplastic nuclei in the image were not labeled. The positive and negative markers in each image were automatically counted, and a labeling index calculated: % Ki-67 = [positive nuclei/(positive nuclei+negative nuclei)]. On this basis, tumors were then classified as grade 1 (Ki-67 index: r2%), grade 2 (Ki-67 index: 3% to 20%), and grade 3 (Ki-67 index: >20%). 3, 43 Categorical data were compared using the w 2 or Fisher exact test. Continuous variables, reported as means with standard deviations (SD), were compared using a student t test. Statistical analyses were performed using the software programs PRISM (GraphPad, San Diego) and Microsoft Excel (Redmond, WA). A P value of <0.05 was considered to be statistically significant.
RESULTS
Three hundred sixty-one pancreatic neoplasms originally classified as PanNETs were reviewed. Of these, 24 were noted to have hyaline globules. Due to the known association between hyaline globules and SPNs, immunolabeling with synaptophysin and b-catenin was performed to confirm whether all 24 cases were truly PanNETs or in fact solid SPNs misclassified as PanNETs ( Fig. 1 , Table 2 ). In 18 of the 24 cases, nuclear labeling for b-catenin was absent (not shown), and synaptophysin was positive (diffusely in 17 cases, focally in 1 case), confirming these neoplasms as true PanNETs (Figs. 1A, B). In 6 of the 24 cases, there was nuclear labeling for bcatenin and cytoplasmic CD10 positivity (not shown), and these neoplasms were reclassified as SPNs (Figs. 1C, D). Synaptophysin immunoreactivity was present in 5 of 6 SPNs and was typically focal (not shown). Therefore, a total of 18 (5%) of 355 histologically confirmed PanNETs in this series contained hyaline globules.
The mean age in years (± SD) for the total number of cases with hyaline globules (n = 24), as well as the confirmed PanNETs (n = 18) and reclassified SPNs (n = 6) was 54.1 (± 13.4), 56 (± 12.4), and 48.3 (± 14.7), respectively (PanNETs vs. SPNs, P = 0.2312). There was no difference in patient gender (PanNETs: 55.6% male vs. SPNs: 50% male, P = 1.000). In 5 (27.8%) of the 18 confirmed PanNETs, the neoplasm was clinically functioning. Three of these were insulin secreting, whereas 2 were glucagon secreting. Two (11.1%) of the 18 confirmed PanNETs arose in patients with multiple endocrine neoplasia type 1.
The mean tumor size in centimeters ( ± SD) for confirmed PanNETs was 4.7 cm (± 2.9). For the reclassified SPNs, it was 6.3 cm (± 6.0) (PanNETs vs. SPNs, P = 0.3720). The body and tail were most frequently involved in confirmed PanNETs (72.1%), whereas the body and head were the most common sites of the reclassified SPNs (33.3% each). Tumors were predominantly unifocal (88.9% PanNETs vs. 100% SPNs, P = 1.000). Both the confirmed PanNETs and reclassified SPNs were most frequently solid (72.2% and 50%, respectively), although they occasionally showed pure cystic or a combination of solid and cystic growth. A statistical comparison of the location distribution, focality, and type of growth in PanNETs versus SPNs was not possible due to the small sample size.
The hyaline globules in the 24 cases ranged dramatically in size, and were both intracytoplasmic and extracellular ( Fig. 1 ). They did not show any unique distribution within the tumor. In both PanNETs and SPNs, they were frequently focal, and therefore no significant differences in their prevalence in PanNETs versus SPNs were readily recognized. In all tested cases, they were PAS positive ( Fig. 2A , Table 2 ) and diastase resistant. Hyaline globules in 12 (80%) of the 15 tested confirmed PanNETs and in 6 (100%) of the 6 tested reclassified SPNs were immunoreactive with a-1-antitrypsin ( Fig. 2B , Table 2 ). In 1 PanNET, the globules were positive for trypsin (not shown). The 24 cases with hyaline globules were histologically re-evaluated to assess whether any features aside from CD10 and nuclear b-catenin labeling could help distinguish PanNETs with hyaline globules from SPNs. All 24 cases were histologically examined for the pattern of invasion, and presence or absence of the following features: microcystic change, hemorrhage, cholesterol clefts, clear cells, foam cells, nuclear grooves, and foci of discohesion within the tumor (Fig. 3 , Table 2 ). Clear cells, characterized by clear cytoplasm and an eccentric nucleus, were 1 feature more commonly seen in SPNs (Fig. 3A , 100% SPNs vs. 27.8% PanNETs, P = 0.0034). An additional feature frequently observed in SPNs was an insidious pattern of invasion ( Fig. 3B ). In this pattern, the neoplastic cells subtly penetrate around and entrap normal pancreatic elements. Insidious invasion was noted in 83.3% of the SPNs and in only 11.1% of the PanNETs (P = 0.0027). Although rare and focal, longitudinal nuclear grooves were more often present in SPNs than PanNETs, whereas the nuclei of PanNETs more commonly were round with speckled chromatin and lacked grooves (Figs. 3C, D; 50% SPNs vs. 0% PanNETs, P = 0.0099). Foci of discohesive, single cells were only rarely present in either neoplasm ( Fig.  3E ), but surprisingly were not statistically more frequent in SPNs (33.3% SPNs vs. 5.6% PanNETs, P = 0.1433). Other features such as foam cells (Fig. 3F ), hyalinization ( Fig. 3G ), cholesterol clefting ( Fig. 3H ), microcystic change (not shown), and hemorrhage (not shown) were compared, but showed no statistically significant differences between SPNs and PanNETs ( Table 2 ). Of the 6 SPNs, 4 were purely solid, with no pseudopapillary or pseudoglandular features, whereas 2 were predominantly solid with only a small focus of discohesion imparting a pseudopapillary appearance.
The PanNETs were assigned a World Health Organization grade of 1, 2, or 3 on the basis of the Ki-67 immunolabeling index. 3, 43 The Ki-67 labeling indices of the SPNs were similarly grouped for purposes of comparison. Fifty percent of confirmed PanNETs versus 66.7% of reclassified SPNs were grade 1, 50% of PanNETs versus 33.3% of SPNs were grade 2, and 0% of either PanNETs or SPNs were grade 3. Using the American Joint Committee on Cancer staging criteria, 6 the primary tumor in cases of confirmed PanNETs was T1 in 22.2%, T2 in 33.3%, and T3 in 44.5% of cases. In cases of reclassified SPNs, the primary tumor was T2 in 100% of cases. zIn some cases, HG were focal and were not present on levels immunolabeled with a-1-antitrypsin (n = 3) or trypsin (n = 2), or those stained with PAS or PASD (n = 2).
CBD indicates cannot be determined; HG, hyaline globules; NT, not tested; PASD, PAS with diastase. 
DISCUSSION
In summary, we identified hyaline globules in 6.6% of 361 neoplasms originally diagnosed as pancreatic neuroendocrine tumors (PanNETs). Although 6 of these cases with hyaline globules were shown to be misdiagnosed solid-pseudopapillary neoplasms (SPNs), the majority were confirmed to be PanNETs with hyaline globules. Thus, although hyaline globules should raise the possibility of SPNs, hyaline globules may also be found in 5% of PanNETs.
There can be considerable morphologic overlap between SPNs and PanNETs. 17, 18, 28, 35 Importantly, we found that several histologic features, in addition to the hyaline globules, can facilitate the distinction between PanNETs and SPNs. An insidious pattern of invasion, clear cells, and nuclear grooves are features which, in addition to immunolabeling with b-catenin, favor SPN. Features such as foam cells, hyalinization, cholesterol clefting, microcystic change, hemorrhage, and foci of discohesion were no different in PanNETs versus SPNs. Relying on pseudopapillary or pseudoglandular features to make the distinction between PanNETs and SPNs was of limited utility: 4 of 6 SPNs were solid with no such features, and 2 of 6 SPNs were predominantly solid with only a small discohesive focus conferring a pseudopapillary appearance.
When confronted with the diagnostic dilemma of PanNET versus SPN, a number of immunomarkers can help establish the correct diagnosis. 3 Notohara et al 34 have reported that CD10, CD56, vimentin, synaptophysin, chromogranin, and pancytokeratin are useful in distinguishing between SPNs and PanNETs. In this study, we advocate a panel of immunomarkers to include synaptophysin, b-catenin, and (if the b-catenin is nuclear) CD10 to make the distinction between PanNETs and SPNs, whether hyaline globules are present or not. Trypsin and chymotrypsin can be included in the panel since acinar cell carcinomas are also solid cellular neoplasms and should be in the differential diagnosis. All 18 PanNETs strongly expressed synaptophysin (diffusely in 17 tumors and focally in 1 tumor). Although 5 of the 6 SPNs were immunoreactive for synaptophysin, such labeling was typically only focal. In contrast, all 18 PanNETs had a membranous pattern of labeling for b-catenin, whereas all 6 SPNs had abnormal nuclear b-catenin immunolabeling and cytoplasmic CD10 staining.
Among 361 tumors originally classified as PanNETs, 18 were true PanNETs with hyaline globules. This corresponds to an incidence of hyaline globules in PanNETs of nearly 5%. The hyaline globules in PanNETs are PAS positive/diastase resistant, and are most frequently immunoreactive with a-1-antitrypsin. Garg et al 10 previously reported a case of a PanNET with PAS positive hyaline globules. This case was of ectopic adrenocorticotropic hormone syndrome in a 12-year-old boy with a PanNET consisting of monomorphic cells and delicate vessels. In this study, only 5 (27.8%) of the PanNETs were clinically functional, 3 of which were insulinomas, 2 of which were glucagonomas, and none of which were adrenocorticotropic hormone secreting. The PanNETs with hyaline globules in our series were often large, a number of which had nodal and distant metastases at the time of initial diagnosis, as well as subsequent metastases.
Six of the 24 cases originally diagnosed as PanNETs were in fact SPNs with hyaline globules. Such globules have long been associated with SPNs, and their presence in a solid cellular neoplasm of the pancreas should raise the possibility of an SPN in the differential diagnosis. 2, 25, 27 As with those in PanNETs, hyaline globules in SPNs were PAS positive/diastase resistant, and were also immunoreactive with a-1-antitrypsin. Unlike PanNETs, however, SPNs typically showed more focal synaptophysin positivity as has been previously documented, 31, 35, 46 and also immunoreactivity with b-catenin (nuclear) and CD10. 1, 33, 34, 49 The clinical importance of correctly distinguishing between SPNs and PanNETs is growing from the standpoints of therapeutics, genetics, and outcome. SPNs are treated surgically; historically, chemoradiation has not played a beneficial role. 24, 29, 58 PanNETs, too, may be surgically resected, and a number of studies have shown that they are also amenable to both chemotherapy and radiation. 4, 26, 30, 41, 47, 51, 53, 54, 57 Among the non-surgical approaches to the treatment of PanNETs are peptide receptor radionuclide therapy, chemotherapy, somatostatin analogs, and interferon. 8 A recent study showed that PanNETs harbor frequent alterations in several genes, including those involved in the mammalian target of the rapamycin (mTOR) pathway. 15 Specific targeted therapies, such as Everolimus, have been shown to be effective in some patients with PanNETs, and these therapies are likely to be effective only in neoplasms, such as PanNETs, in which the mTOR pathway has been activated. 8, 13, 32, 56, 59 Although a few studies have suggested that a proportion of SPNs behave in an aggressive manner, 22, 23, 29, 39, 44, 50, 52 several studies have demonstrated that they have an excellent prognosis. 11, 16, 18, 37 PanNETs can also exhibit a spectrum of behaviors, 5, 7, 9, 12, 19, 20, 38, 43, 45, 55 and their malignant potential may not be readily ascertained histologically.
In conclusion, the morphologic features of SPNs and PanNETs overlap. Small SPNs with minimal degenerative changes are particularly hard to recognize. In these cases, hyaline globules should raise SPNs in the differential diagnosis, and the diagnosis can be established with immunolabeling for b-catenin and CD10. In addition, the presence of hyaline globules should not be used as a sole diagnostic criterion for SPNs, as 5% of PanNETs contain hyaline globules. Features supporting the diagnosis of SPN include nuclear b-catenin labeling and CD10 expression, an insidious pattern of invasion, clear cells, and nuclear grooves.
